An NHANES analysis finds 82.3% of 9.1 million US adults eligible for kidney-protective GLP-1 RA therapy are unaware of their CKD, with no improvement over a decade.
|Articles|April 18, 2023
Rheumatoid Arthritis Quiz: Race and Treatment of RA
Author(s)Ingrid Torjesen
How does race affect treatment for rheumatoid arthritis in the United States? Test your knowledge with this quiz.
Advertisement
Is the following statement true or false?
Black US veterans are less likely to be prescribed a biologic disease-modifying antirheumatic drug (bDMARD) for rheumatoid arthritis when compared with White veterans.
Advertisement
Related to this article
Long-term extension data show iptacopan held a −3.49 mL/min/1.73 m² per year eGFR slope over 48 months, with benefit emerging after patients switched from placebo.
Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.
Final 96-week phase 1b data show sustained UPCR reduction and stable eGFR about 1.5 years after the last mezagitamab dose, with no serious adverse events.
Final VISIONARY data show sibeprenlimab held eGFR steady over 24 months, with a 4.5 mL/min/1.73 m² per year slope advantage and fewer kidney outcome events vs placebo.
Jonathan Barratt, PhD, FRCP, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack final ORIGIN 3 eGFR data for atacicept in IgAN.
In phase 3 INTREPID, lutikizumab beat placebo on HiSCR75 at week 16 and met all 8 ranked secondary end points in moderate to severe HS.
For Eczema Awareness Month, Keira Barr, MD, explains the stress-itch cycle in atopic dermatitis and questions to uncover its hidden burden in clinic.
Advertisement
Advertisement
Trending on HCPLive
1
Tozorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA
2
Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD
3
AAD's New HS Guidelines Flag 'Step Therapy' as Top Barrier to Care
4
Depemokimab Year 1 Remission Linked to Better Year 2 Asthma Outcomes
5